Allogene Therapeutics (ALLO) Leases (2019 - 2025)
Allogene Therapeutics (ALLO) has disclosed Leases for 7 consecutive years, with $39.9 million as the latest value for Q4 2025.
- Quarterly Leases fell 11.76% to $39.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.9 million through Dec 2025, down 11.76% year-over-year, with the annual reading at $39.9 million for FY2025, 11.76% down from the prior year.
- Leases hit $39.9 million in Q4 2025 for Allogene Therapeutics, down from $40.9 million in the prior quarter.
- In the past five years, Leases ranged from a high of $86.8 million in Q2 2022 to a low of $2.4 million in Q3 2024.
- Historically, Leases has averaged $54.0 million across 5 years, with a median of $51.1 million in 2022.
- Biggest five-year swings in Leases: surged 40089.0% in 2021 and later plummeted 96.95% in 2024.
- Year by year, Leases stood at $58.0 million in 2021, then skyrocketed by 44.05% to $83.6 million in 2022, then dropped by 23.79% to $63.7 million in 2023, then decreased by 29.04% to $45.2 million in 2024, then decreased by 11.76% to $39.9 million in 2025.
- Business Quant data shows Leases for ALLO at $39.9 million in Q4 2025, $40.9 million in Q3 2025, and $42.0 million in Q2 2025.